Pancreatic Cancer Research

ResearcherHarvard UniversityNo recent work listed

Amir Avan

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5103764849. Sources: OpenAlex.

Their work

Papers
14 (first author 6, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
47
Papers, trials and grants by year

2012: 2 papers · 2013: 2 papers · 2014: 6 papers · 2015: none · 2016: none · 2017: 2 papers · 2018: none · 2019: 1 paper · 2020: none · 2021: 1 paper

Papers 14

  1. SF3B1 modulators affect key genes in metastasis and drug influx: a new approach to fight pancreatic cancer chemoresistance. Co-author DOI 10.20517/cdr.2021.61↗
  2. Role of c-MET Inhibitors in Overcoming Drug Resistance in Spheroid Models of Primary Human Pancreatic Cancer and Stellate Cells. Co-author DOI 10.3390/cancers11050638↗
  3. Development of bioluminescent chick chorioallantoic membrane (CAM) models for primary pancreatic cancer cells: a platform for drug testing. First author DOI 10.1038/srep44686↗
  4. Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer. First author DOI 10.1186/s13045-016-0371-1↗
  5. miR-211 modulates gemcitabine activity through downregulation of ribonucleotide reductase and inhibits the invasive behavior of pancreatic cancer cells. First author DOI 10.1080/15257770.2014.891741↗
  6. Role of CYB5A in pancreatic cancer prognosis and autophagy modulation. Co-author DOI 10.1093/jnci/djt346↗
  7. AKT1 and SELP polymorphisms predict the risk of developing cachexia in pancreatic cancer patients. First author DOI 10.1371/journal.pone.0108057↗
  8. Galectin-4 expression is associated with reduced lymph node metastasis and modulation of Wnt/β-catenin signalling in pancreatic adenocarcinoma. Co-author DOI 10.18632/oncotarget.2104↗
  9. EGFR as a potential target for the treatment of pancreatic cancer: dilemma and controversies. First author DOI 10.2174/1389450115666141125123003↗
  10. A polymorphism in the promoter is associated with EZH2 expression but not with outcome in advanced pancreatic cancer patients. First author DOI 10.2217/pgs.13.225↗
  11. Prognostic factors in gemcitabine-cisplatin polychemotherapy regimens in pancreatic cancer: XPD-Lys751Gln polymorphism strikes back. Co-author DOI 10.1002/ijc.28078↗
  12. Enhancement of the antiproliferative activity of gemcitabine by modulation of c-Met pathway in pancreatic cancer. Co-author DOI 10.2174/138161213804547312↗
  13. Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells. Co-author DOI 10.1158/1535-7163.mct-12-0037↗
  14. High-throughput microRNA (miRNAs) arrays unravel the prognostic role of MiR-211 in pancreatic cancer. Co-author DOI 10.1371/journal.pone.0049145↗

Closest collaborators

The 25 strongest of 47 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Elisa Giovannetti · 13 shared papers, 2012–2021 · strength 0.65
  2. Godefridus J. Peters · 12 shared papers, 2012–2021 · strength 0.58
  3. Niccola Funel · 11 shared papers, 2012–2019 · strength 0.50
  4. Mina Maftouh · 6 shared papers, 2013–2017 · strength 0.26
  5. Ugo Boggi · 5 shared papers, 2012–2017 · strength 0.19
  6. Enrico Vasile · 4 shared papers, 2012–2014 · strength 0.13
  7. Daniela Carbone · 1 shared paper, 2021 · strength 0.12
  8. Stella Cascioferro · 1 shared paper, 2021 · strength 0.12
  9. Camilla Pecoraro · 1 shared paper, 2021 · strength 0.12
  10. Ornella Randazzo · 1 shared paper, 2021 · strength 0.12
  11. Barbara Parrino · 1 shared paper, 2021 · strength 0.12
  12. Patrizia Diana · 1 shared paper, 2021 · strength 0.12
  13. Andrea Mambrini · 3 shared papers, 2013–2014 · strength 0.11
  14. Maurizio Cantore · 3 shared papers, 2013–2014 · strength 0.11
  15. Majid Ghayour‐Mobarhan · 2 shared papers, 2014 · strength 0.09
  16. Btissame El Hassouni · 1 shared paper, 2019 · strength 0.08
  17. Ilaria Carnevale · 1 shared paper, 2019 · strength 0.08
  18. Thomas Schmidt · 1 shared paper, 2019 · strength 0.08
  19. Stefano Coppola · 1 shared paper, 2019 · strength 0.08
  20. Rainer Lothar Heuchel · 1 shared paper, 2019 · strength 0.08
  21. Pei Pei · 1 shared paper, 2019 · strength 0.08
  22. Omidreza Firuzi · 1 shared paper, 2019 · strength 0.08
  23. Matthias J. Löhr · 1 shared paper, 2019 · strength 0.08
  24. Adam Enver Frampton · 2 shared papers, 2013–2014 · strength 0.08
  25. Maria N. Rovithi · 1 shared paper, 2017 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.